Ing Groep Nv Adr (ING) Holder Iowa State Bank Trimmed Its Position as Stock Rose; Abingworth Llp Has Cut Stake in Cymabay (CBAY) as Stock Value Rose

February 15, 2018 - By Vivian Park

Abingworth Llp decreased its stake in Cymabay (CBAY) by 3.58% based on its latest 2017Q3 regulatory filing with the SEC. Abingworth Llp sold 57,278 shares as the company’s stock rose 21.05% with the market. The institutional investor held 1.54 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $12.42 million, down from 1.60 million at the end of the previous reported quarter. Abingworth Llp who had been investing in Cymabay for a number of months, seems to be less bullish one the $809.53M market cap company. The stock increased 8.47% or $1.14 during the last trading session, reaching $14.6. About 2.01 million shares traded or 163.31% up from the average. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 15, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Iowa State Bank decreased its stake in Ing Groep Nv Adr (ING) by 23.86% based on its latest 2017Q3 regulatory filing with the SEC. Iowa State Bank sold 31,722 shares as the company’s stock rose 17.61% with the market. The institutional investor held 101,203 shares of the finance company at the end of 2017Q3, valued at $1.86M, down from 132,925 at the end of the previous reported quarter. Iowa State Bank who had been investing in Ing Groep Nv Adr for a number of months, seems to be less bullish one the $67.13 billion market cap company. The stock 0.03% or $0 during the last trading session, reaching $18.5. It is down 45.69% since February 15, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Among 9 analysts covering ING Groep N.V. (NYSE:ING), 5 have Buy rating, 1 Sell and 3 Hold. Therefore 56% are positive. ING Groep N.V. had 10 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Goldman Sachs given on Tuesday, January 17. Morgan Stanley downgraded the stock to “Underweight” rating in Thursday, March 31 report. Independent Research downgraded ING Groep N.V. (NYSE:ING) on Wednesday, December 7 to “Hold” rating. The stock of ING Groep N.V. (NYSE:ING) earned “Buy” rating by Deutsche Bank on Thursday, August 27. The rating was upgraded by Kepler Cheuvreux on Friday, February 5 to “Buy”. The rating was upgraded by RBC Capital Markets on Friday, September 23 to “Outperform”. The stock has “Hold” rating by HSBC on Wednesday, May 31. As per Friday, October 9, the company rating was initiated by Natixis. The firm earned “Buy” rating on Tuesday, June 20 by Deutsche Bank.

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The company was initiated on Tuesday, September 8 by H.C. Wainwright. The rating was maintained by H.C. Wainwright on Wednesday, January 24 with “Buy”. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Roth Capital on Friday, July 1. Cantor Fitzgerald maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, October 25 with “Buy” rating. The company was maintained on Tuesday, November 28 by Leerink Swann. Piper Jaffray maintained the stock with “Buy” rating in Monday, July 17 report. H.C. Wainwright maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Monday, July 17. H.C. Wainwright has “Buy” rating and $1200 target. H.C. Wainwright maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Wednesday, January 4. H.C. Wainwright has “Neutral” rating and $2.50 target. Cantor Fitzgerald initiated Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, September 19. Cantor Fitzgerald has “Buy” rating and $16.0 target. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Wednesday, March 30 by H.C. Wainwright.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 earnings per share, up 56.67% or $0.17 from last year’s $-0.3 per share. After $-0.21 actual earnings per share reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10% EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>